The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
: Congrats on all the progress. Maybe just first on the 28-day patient cohort, do you still anticipate enrolling 20 patients or given, sort of, the
lengthening of the study, do you anticipate perhaps enrolling more patients as well? And then if you could just comment on the anticipated mix
between atopic derm and HS patients within that cohort.
And then second, just on the QT prolongation, can you give us just a little bit more color on what was seen, sort of, like the number of patients,
which dose levels and I think you said it wasn't considered grade 1, even" I mean, just any more color would be helpful. And I guess also when you
did the [unwinding] of the safety data, just maybe what dose levels the mild heart palpitations were seen at?
Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: I have 2 questions. First one on the STAT3 program. In the past year, you have communicated potential accelerated approval (inaudible). I guess,
based on the data that you're seeing, seen, have you (inaudible) that view? And also on the program, I see you have amended the protocol to
include a combo study. Can you discuss more - provide more color on how you want to go with that combo study?
Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: I'm going to (inaudible) there (inaudible). And also your IRAKIMiD program, have you seen - I know it's early days - have you seen any QTc findings
in those programs?
|
